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Abstract
Background. Uraemic toxins in the 8 to 60 kDa molecular
weight range have been attracting increasing attention in
dialysis therapy. However, there are no available standar-
dized methods to evaluate their removal. Using new filter-
ingmembranes,weevaluatedSDS–PAGEofspentdialysate
to assess cut-off ranges and removal capacities into dialy-
sate, while also measuring classical markers of dialyser
function.
Methods. Eighteen dialysis patients were washed out for
2 weeks with FX 100 (Helixone
®), followed by rando-
mization to Xevonta Hi 23 (Amembris
®)o rF Xd i a l y s e r s
for 2 weeks, then crossed over for an additional 2 weeks,
and finally placed on Xenium 210 (Purema
®) for 2 weeks.
SDS–PAGE scanning of the removed proteins contained in
the spent dialysate was performed during all dialysis ses-
sions. Total mass of urea, creatinine, total proteins, beta 2
microglobulin (β2m), retinol-binding protein (RBP) and al-
bumin were measured. The reduction rates of serum urea,
creatinine, β2m, leptin, RBP, alpha 1-antitrypsin, albumin
and total proteins were also determined.
Results.SDS–PAGEscanningidentifiedfourmajor protein
peaks (10–18, 20–22.5, 23–30 and 60–80 kDa molecular
weight) and showed clear differences in the amounts of re-
moved proteins between the dialysers, particularly in the
20–22.5, 23–30 and 60–80 kDa ranges. Total mass of re-
moved β2m, RBP and albumin were in agreement with
SDS–PAGE, while serum assays showed differing results.
Conclusions. SDS–PAGE scanning provided a good
characterization of protein patterns in the spent dialysate;
it extended and agreed with protein determinations and al-
lowed a better assessment of dialyser performance in re-
moving 10 to 80 kDa molecular weight substances. It
also identified differences between the three mainly filtrat-
ing polysulfone dialysers that were not detected with blood
measurements.
Keywords: haemodialysis; middle molecules; protein removal into
dialysate; SDS–PAGE; spent dialysate
Introduction
Urea levels have classically been used as a marker of dia-
lysis adequacy [1]. However, there is an impressive list of
solutes that potentially contribute to uraemic toxicity [2],
and this list is still growing [3]. Evidence for participation
of these newly identified culprits in the development of ur-
aemic syndrome and their association with morbidity and
mortality has directed attention to other markers in the 8 to
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dialysis adequacy [4].
Molecules that are difficult to remove by dialysis, such
as these larger middle molecular weight compounds and
protein-bound molecules, play a significant role in uraemic
toxicity [5]. Dialysis manufacturers have developed new
dialysers having improved geometry and new membranes
thatenhanceremovalofmiddlemolecularweightmolecules
withtheaimof improvingclinicaloutcomes[6,7].However,
there are presently no accepted methods that alloweasy and
precise measurement of removal capacities of uraemic re-
tention solutes in the 8 to 60 kDa molecular weight range
by these new generation dialysers. To evaluate dialyser per-
formance, most authors determined variations in blood le-
vels of particular proteins [8]; however, the majority of
manufacturerslimitinformationaboutdialyserperformance
to variations in blood levels of beta 2 microglobulin (β2m)
whichrepresentsquitearestraintamountof information[4].
SDS–PAGE, which was first proposed by Laemmli in
1970 [9], is a reliable method for protein characterization
that is easy to use and has been rendered widely available
in the clinical setting. The aim of the present study was to
assess the usefulness of scanning SDS–PAGE profiles of
proteinscontainedinspent dialysate toevaluatetheremoval
capacities of the new generation high-flux polysulfone dia-
lysers in vivo during routine clinical haemodialysis.
Materials and methods
Patients
Eighteen stable dialysis patients treated in the dialysis centre at Néphro-
logie Dialyse St Guilhem in Sète were included in the study. They were
dialysed three times a week with fully equipped AK200S machines (Gam-
bro, Lund, Sweden) using ultrapure double reverse osmosis water and a
measured dialysate flow of 500 ± 10 mL/min. They had been on dialysis
for more than 3 months and had no active disease at the time of testing.
The study was explained to the patients and they gave informed consent to
participate in the protocol. This study was approved by the Comité de
Protection des Personnes of Nîmes (2009.01.07 bis) and was given a
registration number at the French Agency AFSSAPS 2008-A01612-53.
Study design
A schematic of the study design is given in Figure 1. Three new gener-
ation polysulfone dialysers were assessed. The complete in vitro charac-
teristics of these dialysers are given in Table 1. After 2 weeks of wash out
with FX 100 (Helixone
® membrane, Fresenius Medical Care AG, Bad
Homburg, Germany), the patients were randomized to Xevonta (Xevonta
Hi 23, Amembris
® membrane, B. Braun Avitum, Melsungen, Germany)
(n = 9) or FX dialysers (n = 9) for 2 weeks and then crossed over for an
additional 2 weeks. The eighteen patients were then switched to Xenium
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Fig. 1. Schematic of the study protocol.
Table 1. Dialyser characteristics provided by the manufacturers from in vitro data
Dialyser
Type FX class 100 Xenium 210 Xevonta Hi 23
Membrane (synthetic) Helixone
® Purema
® Amembris
®
Wall thickness/inner diameter (μm) 35/185 30/200 35/195
Surface (m
2) 2.2 2.1 2.3
In vitro KUF 73 80 124
In vitro clearances
(Qb/Qd: 300/500 mL/min)
Urea 278 285 279
Creatinine 261 272 276
Phosphate 248 253 277
Vitamin B12 (1.4 kDa) 192 200 204
Inulin (5 kDa) 142 NA 144
Myoglobin (16.7 kDa) NA 55 NA
Sieving coefficient
Vitamin B12 (1.4 kDa) NA 0.99 NA
Inulin (5 kDa) 1 0.89 1.0
β2 microglobulin (11.8 kDa) 0.8 NA >0.8
Myoglobin (16.7 kDa) NA 0.24 NA
Albumin (65 kDa) 0.001 <0.01 <0.001
NA, not available.
2282 A. Ficheux et al.dialysers (Xenium 210, Purema
® membrane, Baxter Healthcare Corpor-
ation, McGaw Park, IL, USA) for a final 2 weeks. The patients received
routine dialysis prescription criteria that remained constant throughout the
study period.
Adsorption studies
Polysulfone membranes are classically considered as filtrating mem-
branes. In addition to filtering, we also examined the adsorptive capacities
of the new generation polysulfone membranes used in this study.
Helixone
®, Purema
® and Amembris
® dialysers were assessed for ad-
sorption using the technique by Mares et al. [10]. At the end of dialysis
procedures, after returning the blood to the patients, the dialysers were
further rinsed with 2 L of saline. After draining, the dialysers were refilled
with 3 mM EDTA (EDTA/PBS, pH 7.4), and the solution (volume 144 ±
26 mL) was recirculated at 80 mL/min for 30 min at room temperature to
detach and remove adhering leukocytes. The dialysers were then drained
and refilled with 40% acetic acid (volume 195 ± 15 mL), which was re-
circulated at 80 mL/min for 30 min at room temperature. The eluate was
centrifuged to remove cellular detritus and albumin. Then, β2m and total
protein concentration were determined in the supernatant as described
below.
Results of the protein analysis from the adsorption experiments are
shown in Table 2. These data indicate that the amount of total proteins
adsorbed was always <5% of the total amount of proteins that were re-
moved into the dialysate, confirming the filtrating abilities of the new
polysulfone dialysers.
Dialysate studies
Dialysate samples and solute mass removal assessment. In order to assess
total balance of the different substances from serum, continuous sampling
of spent dialysate (CSSD) was performed during each dialysis treatment
as previously reported by our group [11]. Samples were stored at −80°C
until analysis. Urea, creatinine, total protein, albumin (67 kDa), retinol-
binding protein (RBP) (21.2 kDa) and β2m (11.8 kDa) were determined
from the collected spent dialysate, and the total mass removed of a given
substance was calculated by multiplying the measured concentration by
the total volume of dialysate that passed through the dialyser.
The three proteins selected are representative of three of the four mo-
lecular weight ranges of interest (see the SDS–PAGE analyses of the Re-
sults section) and provided an internal control for quantification of protein
content assessed by SDS–PAGE. Since some of the proteins had a con-
centration under the sensitivity threshold for their respective assays, the
spent dialysate was precipitated with 10% trichloroacetic acid.
RBP and leptin were determined by ELISA using specific antibodies
(RD Systems, Lille, France). Albumin was determined by immunoturbi-
dimetry. The sensitivity threshold and the linearity range of the measure-
ments of the different substances are given in Table 3.
SDS–PAGE and scanning of protein profiles. SDS–PAGE of desalted
dialysate was performed according to the method described by Laemmli
[9] using a Bio-Rad system (Bio-Rad laboratories, CA, USA).
Total protein concentrations were assessed from all dialysis sessions
using the Bradford method adapted for the low concentration range as pre-
viouslydescribed[12].Foreachpatient,thedialysateobtainedfromsixdif-
ferent dialyses with the same dialyser was pooled and submitted to SDS–
PAGE. This decreased the variability and the sensitivity of the method, but
increasedthespecificityoftheanalysessuchthatobserveddifferenceswere
more likely to be real. Approximately 10 μg of proteins in 2% SDS buffer
solution were run in a 12.5% SDS–PAGE and then stained with Coomassie
blue. SDS–PAGE gels were scanned with an Epson Perfection 4990
PHOTO (Epson, CA, USA), and the surfaces under the curve of optical
density of the electrophoretic bands for the specified molecular weight
ranges were calculated using WCIF Image J, 1.37 software (WCIF,
ON, Canada). The molecular weight range of the scanning procedure was
normalizedbyfollowingthemigrationofthemolecularweightmarkersand
was divided in 500 readings. The percentage of density for each reading
over the entire density value was calculated. The amount of protein con-
tained in each molecular weight rangewas obtained by multiplying the per-
centage reading by the total protein level of the dialysate obtained with the
Bradford assay and is expressed as the percentage of Coomassie blue-
stained proteins.
Table 3. Laboratory analysis methods and their sensitivity and linearity
Substance
Measurement
method Linearity Sensitivity
Dialysate
(mean ± SD) [min–max]
Blood
(mean ± SD) [min–max]
Urea (mmol/L) UV cinetic 0.8–50 0.38 4.6 ± 1.4 [1.3–9.3] 12 ± 8 [1.6–31]
Creatinine (μmol/L) Compensated Jaffe 5–2000 2.4 85 ± 2 [23–173] 406 ± 230 [73–939]
β2 microglobulin (mg/L) Immunoturbidimetry 0.5–16 0.06 6.5 ± 7.1 [0.06–37] 13.5 ± 5.6 [3.2–23]
Total proteins (dialysate) (g/L) Photometric colour 0.01–2.00 0.007 0.10 ± 0.06 [0.01–0.44]
Total proteins (dialysate) (mg/L) Bradford 0–500 0.002 98 ± 60 [0.002–272]
Total proteins (serum) (g/L) Photometric colour 30–120 0.77 67 ± 7 [52–84]
Albumin ‘micro’ assays (mg/L) Immunoturbidimetry 5–300 0.46 12 ± 14 [0.1–113]
α1-Antitrypsin (g/L) Immunoturbidimetry 0.3–5.0 0.01 1.5 ± 0.3 [0.84–2.44]
Leptin (μg/L)
a ELISA 0.0156–1 0.0078 25 ± 47 [0.6–386]
RBP (mg/L)
a ELISA 1.56–100 0.224 13 ± 7 [1.4–44] 178 ± 96 [55–667]
aLeptin and RBP were diluted before measurement in order to be in the linearity range.
Table 2. Adsorptive capacities of the three dialysers used in the study
Dialyser
Adsorbed proteins
(% of dialysate protein mass)
Adsorbed albumin
(% of dialysate albumin mass)
Adsorbed β2m
(% of dialysate β2m mass)
FX 100 (Helixone) 1.9% 0.5% 1.0%
FX 100 (Helixone) 2.5% 0.3% 0.1%
Xenium 210 (Purema) 1.2% 0.1% 0.2%
Xenium 210 (Purema) 3.5% 2.2% 0.8%
Xevonta Hi 23 (Amembris) 0.8% 0.2% 1.0%
Xevonta Hi 23 (Amembris) 1.4% 0.4% 1.4%
Mean 1.9% 0.6% 0.7%
SE 0.4% 0.3% 0.2%
Max 3.5% 2.2% 1.4%
Min 0.8% 0.1% 0.1%
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Blood was sampled before and after mid-week dialysis sessions. In
addition to the compounds measured in the dialysate studies, alpha 1-
antitrypsin (α1AT) (55 kDa) (immunoturbidimetry) and leptin (16 kDa)
(ELISA) were determined. Post-dialysis values were corrected using the
formula of Bergstrom and Wehle [13].
Clearances (K) were obtained from dialysate mass (M), mean serum
concentration (Cm) and time (T).
K =M=ðCm*TÞ with Cm=ðCpre   CpostÞ =lnðCpre=CpostÞ
Kt/V was calculated from serum urea level as follows:
Kt=V =ln ðCpre=CpostÞ [14].
Dialysance was obtained from Diascan
TM and was iteratively measured
during dialysis.
Statistics
Statistical analyses were performed using SAS V9.01 package (SAS Cor-
poration, N Cary, USA). Differences in the continuous variables among
the three different dialysers were assessed using a variance analysis that
takes into account the repetitive nature of the data. We used a Fisher’s test
with a covariance matrix model and compound symmetry that uses pa-
tients as a random effect and the dialysers as a fixed effect. Bonferroni’s
test was used to assess differences between two of the three groups.
P-values <0.05 were considered significant. Values are expressed as
means ± standard error of the mean.
Results
The dialysis characteristics and the ability of the three
dialysers to remove small molecular weight substances
are presented in Table 4. They were globally equivalent
in their removal capacities of small molecular weight
substances.
SDS–PAGE of spent dialysate
Examples of SDS–PAGE of proteins obtained from the
spent dialysate from the different dialysers are presented
in Figure 2A. A plotting of the density readings, presented
as means ± SEM from the 80 to 10 kDa molecular weight
range, is shown in Figure 2B. There were four major
peaks corresponding to the 10 to 18, 20 to 22.5, 23 to
30 and 60 to 80 kDa molecular weight ranges. The vari-
ability on the density readings from patient to patient was
quite low as indicated by the narrow SEM range. The
amount of Coomassie blue-stained protein contained in
each of these peaks, determined by scanning, is repre-
sented in Figure 3. These data indicate that Amembris
®
removed significantly more protein and particularly those
contained in the 20 to 22.5, 23 to 30 and 60 to 80 molecu-
lar weight ranges.
Single protein determinations and blood studies
Single protein determination in the spent dialysate con-
firmed the SDS–PAGE findings for the different molecu-
lar weight ranges (Figure 4). The actual numbers and
comparisons are given in Table 5. Amembris
® and Helix-
one
® removed significantly more β2m than the Purema
®
dialyser, and Amembris
® removed significantly more al-
bumin and total proteins than the other two dialysers. In-
deed, when analysing the 20–22.5 kDa molecular weight
range, Amembris
® removed significantly more proteins
than the other two dialysers. However, when RBP was
included as a serum protein having a molecular weight in
this molecular weight range, therewas no significant differ-
ence in removal into dialysate between the Amembris
®
and Helixone
® dialysers. Thus, there may be differences
between SDS–PAGE results and results from specific de-
terminations of proteins having a weight in a selected
molecular weight range. This difference is due, at least
in part, to the fact that SDS–PAGE scanning assesses all
Coomassie blue-stained proteins in that molecular weight
range and not just one protein. Thus, it may be that RBP is
not representative of the total amount of proteins in the
molecular weight range found in the spent dialysate.
Blood levels of the selected proteins are represented in
Figure 5. The three dialysers were able to decrease serum
β2m levels by about 60% [Amembris
® 64.3 ± 1, Helix-
one
® 5 8 . 9±1( P<0 . 0 1v sA m e m b r i s
®)a n dP u r e m a
®
59.9 ± 1 (P < 0.01 vs Amembris
®)]. The per cent reduction
of serum levels of compounds having higher molecular
weights decreased to <10% for α1AT and albumin, and
there were no significant differences between the dialysers.
Discussion
In the present study, we assessed the performances of three
new generation, mainly filtrating, high-flux dialysers, hav-
ing large surface areas, high water permeability and equiva-
Table 4. Dialysis characteristics and removal of small molecular weight
solutes
Amembris
® Helixone
® Purema
®
Patient characteristics
Age (years) 79 ± 1.7
BW (kg)
Before 68.8 ± 2.5 68.8 ± 2.5 68.4 ± 2.4
After 66.3 ± 2.3 66.2 ± 2.3 65.8 ± 2.3
WL 2.5 ± 0.3 2.6 ± 0.3 2.6 ± 0.2
Dialysis characteristics
t (min) 222 ± 3 222 ± 3 223 ± 3
Qb (mL/min) 317 ± 2 318 ± 2 319 ± 2
Qd (mL/min) 500 ± 10 500 ± 10 500 ± 10
Urea
Blood before (mmol/L) 19.6 ± 0.9 18.4 ± 0.8 18.0 ± 0.9
Blood after (mmol/L) 4.9 ± 0.3 4.5 ± 0.2 4.7 ± 0.3
Blood RR (%) 75.1 ± 0.8 75.2 ± 0.8 74.2 ± 0.6
Kt/V 1.41 ± 0.03 1.41 ± 0.03 1.37 ± 0.03
Total mass removed
(mmol/session)
528 ± 20 533 ± 18 480 ± 20
K (mL/min) 217 ± 5 217 ± 4 207 ± 2
a
D (mL/min) 219 ± 2 218 ± 2 213 ± 1
a
Creatinine
Blood before (μmol/L) 603 ± 25 620 ± 24 600 ± 25
Blood after (μmol/L) 196 ± 10 199 ± 9 197 ± 9
Blood RR (%) 67.6 ± 0.8 68.3 ± 0.8 67.1 ± 0.9
Total mass removed
(μmol/session)
9645 ± 319 9862 ± 326 9292 ± 346
K (mL/min) 119 ± 3 115 ± 3 113 ± 2
aP < 0.05.
BW, body weight; WL, weight loss during dialysis; Qb, blood flow; Qd,
dialysate flow; RR, reduction ratio; K, clearance; D, ionic dialysance; t,
time; V, urea distribution volume.
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Fig. 2. (A) Examples of 12.5% SDS–PAGE of the proteins in the spent dialysate from the three dialysers tested in the study [1—Xevonta Hi 23
(Amembris
®); 2—FX 100 (Helixone
®); 3—Xenium 210 (Purema
®)]. (B) Scanning profiles of the SDS–PAGE gels of the different dialysers. The
thick line represents the mean value from 18 patients and the thin line is the ±SEM. Protein amount in milligram is represented vertically and
molecular weight is represented horizontally. The units of the readings have been normalized and arbitrarily fixed from 0 to 500. The
correspondence from the reading to molecular weight was not linear and is presented on top of the graph. Four different peaks were observed that
were at the same molecular weight ranges (10–18, 20–22.5, 23–30 and 60–80 kDa) which had different heights for the different dialysers. Numbering of
the panels corresponds as follows: 1—Xevonta Hi 23 (Amembris
®); 2—FX 100 (Helixone
®); 3—Xenium 210 (Purema
®).
Uraemic toxin removal into dialysate by dialysis 2285lent removal characteristics for small molecular weight
compounds. The dialysers were tested in 18 patients given
routine haemodialysis. We assessed both low and high mo-
lecular weight solutes (middle molecules). The protein pro-
files of proteins removed into the dialysate were precisely
determined by gel electrophoresis techniques, and the four
main peaks of proteins were quantified.
Our results show that these three dialysers had similar
capacities for removal of small molecular weight solutes
but differed in their abilities to remove middle molecules
(molecular weight range 8 to 60 kDa) into the dialysate.
SDS–PAGE scanning of the spent dialysate showed that
Amembris
®removedsignificantlymoremiddleweightpro-
teins during routine dialysis.
Although the results of single proteins found in spent
dialysate generally agreed with those from SDS–PAGE
scanning, there were differences between the two tests.
Forexample,althoughAmembris
®andHelixone
®removed
similar amounts of RBP (21 kDa molecular weight), area
under the curve measurements from SDS–PAGE scanning
in the 20 to 22.5 kDa range showed clear differences
between the two dialysers. Since SDS–PAGE includes ana-
lysisofalltheCoomassieblue-stainedproteinscontained in
the sample, it is thought to provide a more complete assess-
ment of protein content in the dialysate than single protein
measurements.
For removal of proteins into the dialysate in the 20 to
80 kDa range, SDS–PAGE scanning again revealed differ-
ences between the three dialysers that the assessment of
blood levels of single proteins did not. For instance, there
were no differences in serum levels of albumin (67 kDa)
between the dialysers, whereas significant differences were
observed in albumin removal into the dialysate. These
differences in sensitivity in measuring dialyser perform-
ance may be due to at least two factors: the different
sample types (blood and spent dialysate) and the different
measurements (single protein determination versus total
amount of proteins included in a range of molecular
weight). The analysis of the spent dialysate allowed mass
estimation of removal into the dialysate, while blood ana-
lysis of selected proteins provided a concentration measure-
ment which is affected by multiple factors (compartmental
distribution of the given protein, shifts in volume distribu-
tion during dialysis and other factors). Furthermore, for
some particular proteins, such as albumin, the amount re-
moved by dialysis is so minor compared to the total pool
that no visible variations in serum levels would be ex-
pected, even when clear differences in removal into the
dialysate exist. It may be that the non-circulating pool
and/or generation rate is such that removed protein is
quickly replaced. Thus, assessment of protein removal,
using blood measurements, is difficult to interpret be-
cause of the multiple factors that affect this measurement.
Alternatively, measuring the removal by determining
what has left the plasma requires analyzing what is ad-
sorbed in the dialysis membrane as well as what passes
across it and is recovered in the spent dialysate. The rela-
tive participation of these two mechanisms in determining
total removal may vary markedly according to membrane
characteristics. PMMA is the classical example of an ad-
sorptive membrane [15], while polysulfone is the classical
example of a filtrating membrane [16–18]. Chanard et al.
[16] assessed decreases in plasma radioactivity after injec-
tion of radiolabelled
131I-β2m. They showed that polysul-
fone was more efficient than PMMA in removing
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2286 A. Ficheux et al.radiolabelled β2m and demonstrated clear differences in
adsorption between the dialysers. The radioactivity recov-
ered from the PMMA membrane was about 90% of that
removed from the plasma, while the radioactivity recov-
ered from the polysulfone membrane was only about
10% of that removed from the plasma, and ~90% had ac-
cumulated in the ultrafiltrate. These studies clearlyconfirm
the filtrating ability of the polysulfone dialysers. Because
weusedthreepolysulfonemembraneswithknownfiltration
characteristics, analysis of the spent dialysate was the best
method to evaluate removal. The error induced by adsorp-
tion onto the membrane over the total mass of the proteins
removed of a defined molecular weight range is minimized
when using polysulfone [17,18]. In our hands, the amount
of protein recovered from the dialyser membrane while as-
sessing adsorption (see Materials and methods section and
Table 2) was <5% of the total mass of proteins that crossed
the membrane and that were obtained in the spent dialysate
(1.9 ± 0.4%, 0.6 ± 0.3% and 0.7 ± 0.2% for total proteins,
albumin and β2m, respectively).
Table 5. Middle molecular weight solute removal
Dialyser
Xevonta Hi 23 FX 100 Xenium 210
Amembris
® Helixone
® Purema
®
β2m
Blood before (mg/L) 18.4 ± 0.4 19.3 ± 0.4 18.6 ± 0.4
Corrected blood after (mg/L) 6.6 ± 0.3 8.0 ± 0.3 7.5 ± 0.3
a,b
Blood RR (%) 64.3 ± 0.9 58.9 ± 1.0 59.9 ± 1.1
a,b
Dialysate concentration (mg/L) 1.29 ± 0.05 1.14 ± 0.07 0.99 ± 0.05
b
Total dialysate mass (mg) 146 ± 6 130 ± 8 110 ± 7
b,c
K (mL/min) 51 ± 3 54 ± 3 30 ± 2
b,c
Leptin
Blood before (μg/L) 34.7 ± 12.3 43.0 ± 17.5 26.0 ± 6.5
Corrected blood after (mg/L) 15.4 ± 5.1 18.2 ± 7.0 13.4 ± 2.9
Blood RR (%) 31.8 ± 4.7 27.7 ± 5.2 28.7 ± 4.4
RBP
Blood before (mg/L) 195.5 ± 26.6 160.4 ± 15.0 206.9 ± 20.5
Corrected blood after (mg/L) 142.2 ± 18.2 126.0 ± 13.6 163.9 ± 14.7
Blood RR (%) 22.4 ± 4.0 20.6 ± 4.1 18.2 ± 2.5
Dialysate concentration (mg/L) 1.58 ± 0.20 1.19 ± 0.14 0.90 ± 0.07
b
Total dialysate mass (mg) 179.4 ± 23.4 136.5 ± 16.3 104.4 ± 8.7
b
K (mL/min) 7.0 ± 1.2 4.8 ± 0.6 3.2 ± 0.4
b
α1-Antitrypsin
Blood before (g/L) 1.53 ± 0.05 1.50 ± 0.05 1.42 ± 0.04
Corrected blood after (mg/L) 1.38 ± 0.04 1.36 ± 0.04 1.29 ± 0.04
Blood RR (%) 9.4 ± 0.9 8.9 ± 1.0 8.7 ± 0.9
Albumin
Blood before (g/L) 36.9 ± 0.5 36.5 ± 0.5 36.7 ± 0.4
Corrected blood after (g/L) 33.6 ± 0.6 33.0 ± 0.5 33.5 ± 0.5
Blood RR (%) 9.0 ± 0.9 9.2 ± 0.9 8.7 ± 0.8
Dialysate concentration (mg/L) 1.19 ± 0.14 0.80 ± 0.09 0.66 ± 0.04
a,b
Total dialysate mass (mg) 133.1 ± 15.7 89.4 ± 9.3 71.4 ± 5.4
a,b
K (mL/min) 0.017 ± 0.003 0.017 ± 0.003 0.008 ± 0.001
b,c
Total proteins
Blood before (g/L) 64.6 ± 0.8 61.4 ± 0.8 64.1 ± 0.7
a,c
Corrected blood after (g/L) 58.7 ± 0.9 55.8 ± 0.7 58.5 ± 0.7
a,c
Blood RR (%) 9.0 ± 0.8 8.8 ± 1.0 8.6 ± 0.9
Dialysate concentration (mg/L) 10.7 ± 0.7 7.1 ± 0.5 7.6 ± 0.4
a,b
Total dialysate mass (mg) 1209 ± 74 810 ± 55 809 ± 52
a,b
K (mL/min) 0.09 ± 0.01 0.08 ± 0.01 0.05 ± 0.01
b,c
aP < 0.05 Xevonta vs FX.
bP < 0.05 Xevonta vs Xenium.
cP < 0.05 FX vs Xenium.
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Fig. 5. Blood measurements: reduction rate of the different serum
proteins. The reduction rate for the measured proteins decreased from
about 60% to <10% as molecular weight increased from 12 to 67 kDa.
β2m reduction was significantly higher with Amembris
® than with the
other dialysers; serum levels of the other proteins showed a similar
decrease in the three dialysers.
Uraemic toxin removal into dialysate by dialysis 2287Proteomics have previously been proposed as a promis-
ing analytical tool for recognizing specific peptide profiles
in different pathological situations [19,20], to assess ur-
aemic toxin removal and to identify new molecules with
putative influences on uraemic toxicity [21]. Weissinger
et al. [21] identified 1046 and 1394 polypeptides using
low- and high-flux membranes, respectively, in the ultrafil-
trate of one dialysed patient. However, this technique, per-
fectly adapted to identifying new markers of disease, is still
reservedto a few specialized laboratories and it is not, at the
present time, envisaged as a toll of wide use to quantify dia-
lysis in a repetitive way in routine clinical practice.
Although SDS–PAGE technique provides semiquantita-
tive data, it has previously been used to test protein perme-
ability of different dialysers at various times during
dialysis sessions using silver staining and laser densitom-
etry [22]. For example, Mann and colleagues [22] used it
to identify significant differences in permeability during
individual dialysis sessions. In our study, we attempted
to adapt SDS–PAGE into a reliable and easy-to-use
method that can be performed in any dialysis unit to assess
total amounts of middle weight molecules removed during
a complete dialysis session.
To make this method easier, we adopted Coomassie blue
staining of the gels. Although this technique is less sensi-
tive than silver staining, it is not influenced by as many
factors, it is technically simpler, and is not as expensive.
To render it more reliable, we assessed the spent dialysate
obtained by the CSSD, which we have previously shown to
perfectly reflect the total spent dialysate [11]. Therefore,
our current results did not show the intra-dialysis varia-
tions that had previously been observed [22], allowing us
to accurately evaluate dialysis performance during a
complete dialysis session, regardless of intra-session vari-
ability. The sensitivity provided by our method, using a
standardized optical analysis over a molecular weight
scale, proved to be satisfactory since it allowed identifica-
tion of clear differences between the dialysers that could
not be observed using other approaches (single protein de-
terminations and blood measurements). Finally, the reli-
ability of the method was supported by the small range
of SEM observed in our analyses.
Conclusion
In summary, the present study showed that scanning the
SDS–PAGE profile of middle weight molecules contained
in the spent dialysate obtained by CSSD is a reliable and
easy-to-use method that allowed identification of differ-
ences in behaviour of three new generation high perme-
ability polysulfone dialysers. Using this method, we
observed (i) very high efficacy and no difference in ability
to remove small molecular weight compounds; (ii) that
Amembris
® removed significantly more proteins at all
weight ranges than Purema
®, but only at higher molecular
weights than Helixone
®; (iii) that Amembris
® and Helix-
one
® removed significantly more β2m than Purema
®,
which agrees with the SDS–PAGE scanning results, and
that Amembris
® removed more total proteins than the
other two dialysers; (iv) that β2m reduction differed
among the three dialysers only when measuring serum le-
vels of the representative proteins, indicating that serum
levels may be influenced by many factors other than re-
moval into dialysate; therefore, (v) measurement of serum
levels of single proteins is not the best approach to assess
uraemic toxin removal capacities by new dialysers, particu-
larly for the middle weight molecules. Since adsorption
contributes to <5% of total protein removal and was
equivalent in the three dialysers, the differences in dialyser
performance were due to differences in removal into the
dialysate.
Many different substances are removed from the plasma;
some of these are uraemic retention solutes, some may be
considered toxins [2] and some may even have beneficial
properties. Therefore,to establishthe benefits ordrawbacks
of substance removal, it will be necessary to better identify,
probably using MS-based techniques, the complete array of
substancesremoved.However,itmaybeeasiertoinstalland
perform SDS–PAGE in a dialysis unit than other techniques
that require more complex technologies. The use of SDS–
PAGE scanning of spent dialysate in many dialysis units
would enlarge our knowledge about how the different dia-
lysis settings are able to remove uraemic toxins of greater
importance (8–60 kDa molecular weight range).
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Abstract
Background. Sleep-disordered breathing (SDB), charac-
terized by repetitive apnea and hypopnea during sleep, is
a risk factor for cardiovascular disease. However, the links
between SDB and cardiovascular events in hemodialysis
(HD) patients have not been clearly evaluated.
Methods. We followed the clinical outcome of 94 HD
patients, who underwent overnight pulse oximetry on
dialysis day. The SDB group was defined as 3% oxygen
desaturation index (ODI) over five events per hour, and the
others were the normal group. The primary outcome was
cardiovascular events and death. We used Kaplan–Meier
curve and Cox proportional hazard model for survival
analyses.
Results. Forty-four patients (46.8%) were classified into
the SDB group. Body mass index, diabetes mellitus, 3%
ODIandEpworthsleepinessscaleweresignificantlyhigher,
and duration of dialysis, Kt/V, normalized protein catabol-
ism rate and hemoglobin were lower in the SDB group
than in the normal group. During a median 55 months of
follow-up, Kaplan–Meier analysis revealed that the SDB
group had a significantly higher rate of cardiovascular
events and all-cause mortality than the normal group.
Age, cardiothoracic ratio, serum albumin and 3% ODI
were predictors of cardiovascular events and all-cause mor-
tality at univariate Cox regression analysis. In the adjusted
analysis, SDB is an independent predictor of increased car-
diovascular events (hazard ratio 3.10; 95% confidence
interval (CI), 1.35–7.12; P = 0.008) and all-cause mortality
(hazard ratio 2.81; 95% CI, 1.07–7.41; P = 0.037).
Conclusions. SDB is an independent risk factor for cardio-
vascular events and mortality in HD patients. Effective and
SDB predicts cardiovascular events 2289
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